The reduced number of TCR-transgenic SP CD4+ thymocytes (Figure 7B) and reduced percentage of peripheral CD4+ T cells (data not shown) in mice with tumor compared to tumor-free mice, independent of SH2D2A expression, is consistent with these previous results. This evidence concerns the gene CD4 and neoplasm.